Plasma microRNA alterations between EGFR-activating mutational NSCLC patients with and without primary resistance to TKI

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have obtained excellent therapeutic effects against non-small cell lung cancer (NSCLC) harboring activating EGFR mutations. However, some patients have exhibited primary resistance which becomes a major obstacle in effective t...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Ma, Yihan, Pan, Xiaoyan, Xu, Peiqi, Mi, Yanjun, Wang, Wenyi, Wu, Xiaoting, He, Qi, Liu, Xinli, Tang, Weiwei, An, Han-Xiang
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2017
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5687624/
https://ncbi.nlm.nih.gov/pubmed/29179454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19874
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы